PMID: 30160394Aug 31, 2018Paper

Antihyperglycemic medications for cardiovascular disease risk reduction

The American Journal of Managed Care
Jennifer D Goldman

Abstract

In recognition of the substantial prevalence of cardiovascular disease-related comorbidities among patients with diabetes and the potential for some agents to increase this risk, evaluation of cardiovascular outcomes is now a standard component of late-stage clinical trials involving antihyperglycemic agents. While most agents are evaluated in noninferiority trials to establish a lack of cardiovascular-related harm, a few agents have shown significant reductions in cardiovascular-related outcomes, including mortality.

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Related Papers

The New England Journal of Medicine
Laura Mauri, Ralph B D’Agostino
The New England Journal of Medicine
Peter DoshiJohn H Powers
The New England Journal of Medicine
Silvio Garattini, Vittorio Bertele’
The New England Journal of Medicine
Stefan Lange
© 2022 Meta ULC. All rights reserved